Biotechnology

Aclarion, Inc. said it has signed a commercial agreement with Weill Cornell Medicine. The deal brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and to a multidisciplinary spine team led by physician and principal investigator Jaspal Ricky Singh, MD. The agreement is also tied to a study titled A…more

Jeffco-based TriSalus Life Sciences Inc. has appointed Richard Marshall as its chief medical officer on a full-time basis, effective June 29, 2026. He will move into the role from his position as medical director, which he has held since January 2025. In the new role, Marshall will lead the company’s medical strategy and provide clinical…more

Aclarion Inc. has announced a strategic dual-approach to its corporate governance and commercial growth, combining a new defensive shareholder measure with an optimistic roadmap for its AI-driven medical technology. The company board of directors has officially adopted a limited-duration stockholder rights plan. This measure is designed to protect the company and its investors from any…more

Highridge Medical, based in Westminster, has announced the limited U.S. launch of a disc designed for patients with lumbar disc degeneration. The company has completed initial surgeries at several disc replacement centers nationwide as part of this rollout. Highridge Medical collaborated with leading surgeons to facilitate the early adoption of this new treatment option, which…more

Aclarion, Inc. has published its 2026 Shareholder Letter, detailing the company’s clinical and financial strategies as it progresses through its clinical trial for treating chronic low back pain. Aclarion expects an internal readout of the 300-patient CLARITY trial by the end of Q3 and plans to publicly disclose preliminary results in Q4 of 2026. The…more

Broomfield-based Aclarion, a healthcare technology company, has completed a $10.4 million financing round at $5.18 per share. This clean capital raise significantly strengthens the company’s financial position, preserves its capital structure, and extends its operational timeline, allowing continued development of its pain identification technology. The increased capital is aimed at enhancing Aclarion’s commercialization efforts, generating…more

Aclarion, a Broomfield healthcare technology company focused on treating chronic low back pain, announced the enrollment of its first patients at two additional clinical trial sites, Northwestern Medicine and Scripps Health. This development advances the enrollment progress for its pivotal CLARITY trial. The CLARITY trial is designed to evaluate whether a new technology, Nociscan, can…more

Aclarion, a healthcare technology company focused on chronic low back pain, has announced the appointment of Jason Brosniak as Commercial Director for the Eastern U.S. This move is aimed at expanding market adoption and payer engagement for the company’s innovative technology, Nociscan. Brosniak brings over 20 years of experience in driving revenue growth for MedTech…more

Hannah Whipple-Macedo, a Senior Program Manager Consultant with a focus on drug development, has been featured in the Influential Women for Impact in Biotech and Pharma program. With over a decade of experience, she has played a crucial role in supporting biotechnology and pharmaceutical teams throughout the complex execution of their projects. Whipple-Macedo has worked…more

PharmaJet has signed a Distribution Agreement with ATR, an affiliate of EVA Pharma, aimed at enhancing access to needle-free vaccinations in Egypt and the broader region. The agreement was finalized on October 30, 2025, during the CPHI meeting in Frankfurt. It includes arrangements for the distribution, technology transfer, and manufacturing of PharmaJet’s needle-free injection technology.…more